

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Jockers et al.

Examiner: N/A

Art Unit: N/A

Application No.: 10/774,721

Filed: February 9, 2004

Title: **Oligonucleotides Which Inhibit
Expression Of the OB-RGRP Protein
And Method For Detecting Compounds
Which Modify The Interaction Between
Proteins Of the OB-RGRP Family and
The Leptin Receptor**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Mail Stop
Sequence, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on

Aug. 12, 2004
Date of Deposit
Dalea Cougle
Signature

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,

F. Aaron Dubberley
F. Aaron Dubberley, Reg. No. 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3737
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005USNP